APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Recombinant DNA Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Recombinant DNA Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174031350323 December 2025198 pages

Choose your research edition.

Industry ResearchRecombinant DNA Drug Industry Research Report 2026140 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant DNA Drug Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Recombinant DNA Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant DNA Drug Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant DNA Drug Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Recombinant DNA Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Recombinant DNA Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recombinant DNA Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant DNA Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Recombinant DNA Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Recombinant DNA Drug include GenSci, Takeda, CSPC, 3SBIO, Sandoz, Sanofi, Johnson & Johnson, Novo Nordisk and Merck, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Recombinant DNA Drug market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recombinant DNA Drug and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recombinant DNA Drug revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Recombinant DNA Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Recombinant DNA Drug Segment by Company

GenSci

Takeda

CSPC

3SBIO

Sandoz

Sanofi

Johnson & Johnson

Novo Nordisk

Merck

Roche

Eli Lilly

Pfizer

GlaxoSmithKline

Biogen

Bayer

Bristol-Myers Squibb

Amgen

AbbVie

Swedish Orphan Biovitrum

Organon Pharma

Recombinant DNA Drug Segment by Type

Fusion Protein

Recombinant Interleukin

Recombinant Interferon

Recombinant Hormone

Recombinant Coagulation Factor

Recombinant Growth Factor

Other

Recombinant DNA Drug Segment by Application

Infectious Diseases

Metabolic Disorders

Cancers

Autoimmune Diseases

Recombinant DNA Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant DNA Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant DNA Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant DNA Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Recombinant DNA Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Recombinant DNA Drug industry.

Chapter 3: Detailed analysis of Recombinant DNA Drug companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Recombinant DNA Drugrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Recombinant DNA Drug Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Fusion Protein Table 3. Key Players of Recombinant Interleukin Table 4. Key Players of Recombinant Interferon Table 3. Key Players of Recombinant Hormone Table 4. Key Players of Recombinant Coagulation Factor Table 5. Key Players of Recombinant Growth Factor Table 6. Key Players of Other Table 7. Global Recombinant DNA Drug Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 8. Key Players of Infectious Diseases Table 9. Key Players of Metabolic Disorders Table 10. Key Players of Cancers Table 11. Key Players of Autoimmune Diseases Table 12. Global Recombinant DNA Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Recombinant DNA Drug Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Recombinant DNA Drug Market Share by Region (2021-2026) Table 15. Global Recombinant DNA Drug Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Recombinant DNA Drug Market Share by Region (2027-2032) Table 17. Recombinant DNA Drug Industry Trends Table 18. Recombinant DNA Drug Industry Drivers Table 19. Recombinant DNA Drug Industry Opportunities and Challenges Table 20. Recombinant DNA Drug Industry Restraints Table 21. Global Recombinant DNA Drug Revenue by Company (US$ Million) & (2021-2026) Table 22. Global Recombinant DNA Drug Revenue Market Share by Company (2021-2026) Table 23. Global Recombinant DNA Drug Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 24. Global Recombinant DNA Drug Key Company Head Office and Area Served Table 25. Global Recombinant DNA Drug Company, Product Type & Application Table 26. Global Recombinant DNA Drug Company Establishment Date Table 27. Global Company Market Concentration Ratio (CR5 and HHI) Table 28. Global Recombinant DNA Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 29. Global Recombinant DNA Drug Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Recombinant DNA Drug Market Size by Type (2021-2026) & (US$ Million) Table 31. Global Recombinant DNA Drug Market Size by Type (2027-2032) & (US$ Million) Table 32. Global Recombinant DNA Drug Revenue Market Share by Type (2021-2026) Table 33. Global Recombinant DNA Drug Revenue Market Share by Type (2027-2032) Table 34. Global Recombinant DNA Drug Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Recombinant DNA Drug Market Size by Application (2021-2026) & (US$ Million) Table 36. Global Recombinant DNA Drug Market Size by Application (2027-2032) & (US$ Million) Table 37. Global Recombinant DNA Drug Revenue Market Share by Application (2021-2026) Table 38. Global Recombinant DNA Drug Revenue Market Share by Application (2027-2032) Table 39. GenSci Company Information Table 40. GenSci Business Overview Table 41. GenSci Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. GenSci Recombinant DNA Drug Product Portfolio Table 43. GenSci Recent Development Table 44. Takeda Company Information Table 45. Takeda Business Overview Table 46. Takeda Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Takeda Recombinant DNA Drug Product Portfolio Table 48. Takeda Recent Development Table 49. CSPC Company Information Table 50. CSPC Business Overview Table 51. CSPC Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. CSPC Recombinant DNA Drug Product Portfolio Table 53. CSPC Recent Development Table 54. 3SBIO Company Information Table 55. 3SBIO Business Overview Table 56. 3SBIO Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. 3SBIO Recombinant DNA Drug Product Portfolio Table 58. 3SBIO Recent Development Table 59. Sandoz Company Information Table 60. Sandoz Business Overview Table 61. Sandoz Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Sandoz Recombinant DNA Drug Product Portfolio Table 63. Sandoz Recent Development Table 64. Sanofi Company Information Table 65. Sanofi Business Overview Table 66. Sanofi Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Sanofi Recombinant DNA Drug Product Portfolio Table 68. Sanofi Recent Development Table 69. Johnson & Johnson Company Information Table 70. Johnson & Johnson Business Overview Table 71. Johnson & Johnson Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Johnson & Johnson Recombinant DNA Drug Product Portfolio Table 73. Johnson & Johnson Recent Development Table 74. Novo Nordisk Company Information Table 75. Novo Nordisk Business Overview Table 76. Novo Nordisk Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Novo Nordisk Recombinant DNA Drug Product Portfolio Table 78. Novo Nordisk Recent Development Table 79. Merck Company Information Table 80. Merck Business Overview Table 81. Merck Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Merck Recombinant DNA Drug Product Portfolio Table 83. Merck Recent Development Table 84. Roche Company Information Table 85. Roche Business Overview Table 86. Roche Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Roche Recombinant DNA Drug Product Portfolio Table 88. Roche Recent Development Table 89. Eli Lilly Company Information Table 90. Eli Lilly Business Overview Table 91. Eli Lilly Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 92. Eli Lilly Recombinant DNA Drug Product Portfolio Table 93. Eli Lilly Recent Development Table 94. Pfizer Company Information Table 95. Pfizer Business Overview Table 96. Pfizer Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 97. Pfizer Recombinant DNA Drug Product Portfolio Table 98. Pfizer Recent Development Table 99. GlaxoSmithKline Company Information Table 100. GlaxoSmithKline Business Overview Table 101. GlaxoSmithKline Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 102. GlaxoSmithKline Recombinant DNA Drug Product Portfolio Table 103. GlaxoSmithKline Recent Development Table 104. Biogen Company Information Table 105. Biogen Business Overview Table 106. Biogen Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 107. Biogen Recombinant DNA Drug Product Portfolio Table 108. Biogen Recent Development Table 109. Bayer Company Information Table 110. Bayer Business Overview Table 111. Bayer Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 112. Bayer Recombinant DNA Drug Product Portfolio Table 113. Bayer Recent Development Table 114. Bristol-Myers Squibb Company Information Table 115. Bristol-Myers Squibb Business Overview Table 116. Bristol-Myers Squibb Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 117. Bristol-Myers Squibb Recombinant DNA Drug Product Portfolio Table 118. Bristol-Myers Squibb Recent Development Table 119. Amgen Company Information Table 120. Amgen Business Overview Table 121. Amgen Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 122. Amgen Recombinant DNA Drug Product Portfolio Table 123. Amgen Recent Development Table 124. AbbVie Company Information Table 125. AbbVie Business Overview Table 126. AbbVie Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 127. AbbVie Recombinant DNA Drug Product Portfolio Table 128. AbbVie Recent Development Table 129. Swedish Orphan Biovitrum Company Information Table 130. Swedish Orphan Biovitrum Business Overview Table 131. Swedish Orphan Biovitrum Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 132. Swedish Orphan Biovitrum Recombinant DNA Drug Product Portfolio Table 133. Swedish Orphan Biovitrum Recent Development Table 134. Organon Pharma Company Information Table 135. Organon Pharma Business Overview Table 136. Organon Pharma Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 137. Organon Pharma Recombinant DNA Drug Product Portfolio Table 138. Organon Pharma Recent Development Table 139. North America Recombinant DNA Drug Market Size by Type (2021-2026) & (US$ Million) Table 140. North America Recombinant DNA Drug Market Size by Type (2027-2032) & (US$ Million) Table 141. North America Recombinant DNA Drug Market Size by Application (2021-2026) & (US$ Million) Table 142. North America Recombinant DNA Drug Market Size by Application (2027-2032) & (US$ Million) Table 143. North America Recombinant DNA Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 144. North America Recombinant DNA Drug Market Size by Country (2021-2026) Table 145. North America Recombinant DNA Drug Market Size by Country (2027-2032) Table 146. Europe Recombinant DNA Drug Market Size by Type (2021-2026) & (US$ Million) Table 147. Europe Recombinant DNA Drug Market Size by Type (2027-2032) & (US$ Million) Table 148. Europe Recombinant DNA Drug Market Size by Application (2021-2026) & (US$ Million) Table 149. Europe Recombinant DNA Drug Market Size by Application (2027-2032) & (US$ Million) Table 150. Europe Recombinant DNA Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 151. Europe Recombinant DNA Drug Market Size by Country (2021-2026) Table 152. Europe Recombinant DNA Drug Market Size by Country (2027-2032) Table 153. China Recombinant DNA Drug Market Size by Type (2021-2026) & (US$ Million) Table 154. China Recombinant DNA Drug Market Size by Type (2027-2032) & (US$ Million) Table 155. China Recombinant DNA Drug Market Size by Application (2021-2026) & (US$ Million) Table 156. China Recombinant DNA Drug Market Size by Application (2027-2032) & (US$ Million) Table 157. Asia Recombinant DNA Drug Market Size by Type (2021-2026) & (US$ Million) Table 158. Asia Recombinant DNA Drug Market Size by Type (2027-2032) & (US$ Million) Table 159. Asia Recombinant DNA Drug Market Size by Application (2021-2026) & (US$ Million) Table 160. Asia Recombinant DNA Drug Market Size by Application (2027-2032) & (US$ Million) Table 161. Asia Recombinant DNA Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 162. Asia Recombinant DNA Drug Market Size by Country (2021-2026) Table 163. Asia Recombinant DNA Drug Market Size by Country (2027-2032) Table 164. South America, Middle East & Africa Recombinant DNA Drug Market Size by Type (2021-2026) & (US$ Million) Table 165. South America, Middle East & Africa Recombinant DNA Drug Market Size by Type (2027-2032) & (US$ Million) Table 166. South America, Middle East & Africa Recombinant DNA Drug Market Size by Application (2021-2026) & (US$ Million) Table 167. South America, Middle East & Africa Recombinant DNA Drug Market Size by Application (2027-2032) & (US$ Million) Table 168. South America, Middle East & Africa Recombinant DNA Drug Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 169. South America, Middle East & Africa Recombinant DNA Drug Market Size by Country (2021-2026) Table 170. South America, Middle East & Africa Recombinant DNA Drug Market Size by Country (2027-2032) Table 171. Research Programs/Design for This Report Table 172. Authors List of This Report Table 173. Secondary Sources Table 174. Primary Sources List of Figures Figure 1. Recombinant DNA Drug Product Image Figure 2. Global Recombinant DNA Drug Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Recombinant DNA Drug Market Share by Type: 2025 VS 2032 Figure 4. Fusion Protein Image Figure 5. Recombinant Interleukin Image Figure 6. Recombinant Interferon Image Figure 7. Recombinant Hormone Image Figure 8. Recombinant Coagulation Factor Image Figure 9. Recombinant Growth Factor Image Figure 10. Other Image Figure 11. Global Recombinant DNA Drug Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 12. Global Recombinant DNA Drug Market Share by Application: 2025 VS 2032 Figure 13. Infectious Diseases Image Figure 14. Metabolic Disorders Image Figure 15. Cancers Image Figure 16. Autoimmune Diseases Image Figure 17. Global Recombinant DNA Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 18. Global Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 19. Global Recombinant DNA Drug Market Share by Region: 2025 VS 2032 Figure 20. Years Considered Figure 21. Global Recombinant DNA Drug Market Share by Players in 2025 Figure 22. Global Top 5 and 10 Recombinant DNA Drug Players Market Share by Revenue in 2025 Figure 23. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 24. Global Recombinant DNA Drug Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Recombinant DNA Drug Revenue Market Share by Type (2021-2032) Figure 26. Global Recombinant DNA Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Recombinant DNA Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 29. North America Recombinant DNA Drug Market Share by Type (2021-2032) Figure 30. North America Recombinant DNA Drug Market Share by Application (2021-2032) Figure 31. North America Recombinant DNA Drug Market Share by Country (2021-2032) Figure 32. United States Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 33. Canada Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 34. Mexico Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 35. Europe Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 36. Europe Recombinant DNA Drug Market Share by Type (2021-2032) Figure 37. Europe Recombinant DNA Drug Market Share by Application (2021-2032) Figure 38. Europe Recombinant DNA Drug Market Share by Country (2021-2032) Figure 39. Germany Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 40. France Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 41. U.K. Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 42. Italy Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 43. Russia Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 44. Nordic Countries Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 45. China Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 46. China Recombinant DNA Drug Market Share by Type (2021-2032) Figure 47. China Recombinant DNA Drug Market Share by Application (2021-2032) Figure 48. Asia Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 49. Asia Recombinant DNA Drug Market Share by Type (2021-2032) Figure 50. Asia Recombinant DNA Drug Market Share by Application (2021-2032) Figure 51. Asia Recombinant DNA Drug Market Share by Country (2021-2032) Figure 52. Japan Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 53. South Korea Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 54. Taiwan Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 55. Southeast Asia Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 56. India Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 57. Australia Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 58. South America, Middle East & Africa Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 59. South America, Middle East & Africa Recombinant DNA Drug Market Share by Type (2021-2032) Figure 60. South America, Middle East & Africa Recombinant DNA Drug Market Share by Application (2021-2032) Figure 61. South America, Middle East & Africa Recombinant DNA Drug Market Share by Country (2021-2032) Figure 62. Brazil Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 63. South Africa Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 64. Saudi Arabia Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 65. Turkey Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 66. Argentina Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 67. UAE Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 68. Egypt Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 69. Chile Recombinant DNA Drug Market Size (2021-2032) & (US$ Million) Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Fusion Protein
  • Recombinant Interleukin
  • Recombinant Interferon
  • Recombinant Hormone
  • Recombinant Coagulation Factor
  • Recombinant Growth Factor
  • Other
Applications
  • Infectious Diseases
  • Metabolic Disorders
  • Cancers
  • Autoimmune Diseases
Companies covered
  • GenSci
  • Takeda
  • CSPC
  • 3SBIO
  • Sandoz
  • Sanofi
  • Johnson & Johnson
  • Novo Nordisk
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • GlaxoSmithKline
  • Biogen
  • Bayer
  • Bristol-Myers Squibb
  • Amgen
  • AbbVie
  • Swedish Orphan Biovitrum
  • Organon Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Recombinant DNA Drug Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Fusion Protein
  5. 1.2.3 Recombinant Interleukin
  6. 1.2.4 Recombinant Interferon
  7. 1.2.5 Recombinant Hormone
  8. 1.2.6 Recombinant Coagulation Factor
  9. 1.2.7 Recombinant Growth Factor
  10. 1.2.8 Other
  11. 1.3 Market Analysis by Application
  12. 1.3.1 Global Recombinant DNA Drug Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  13. 1.3.2 Infectious Diseases
  14. 1.3.3 Metabolic Disorders
  15. 1.3.4 Cancers
  16. 1.3.5 Autoimmune Diseases
  17. 1.4 Global Market Growth Prospects
  18. 1.5 Global Recombinant DNA Drug Growth Trends by Region
  19. 1.5.1 Global Recombinant DNA Drug Market Size by Region: 2021 VS 2025 VS 2032
  20. 1.5.2 Recombinant DNA Drug Market Size by Region (2021-2026)
  21. 1.5.3 Recombinant DNA Drug Market Size by Region (2027-2032)
  22. 1.6 Assumptions and Limitations
  23. 1.7 Study Goals and Objectives
  24. 1.8 Years Considered
2 Global Recombinant DNA Drug Market Dynamics
  1. 2.1 Recombinant DNA Drug Industry Trends
  2. 2.2 Recombinant DNA Drug Industry Drivers
  3. 2.3 Recombinant DNA Drug Industry Opportunities and Challenges
  4. 2.4 Recombinant DNA Drug Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Recombinant DNA Drug Revenue by Company (2021-2026)
  2. 3.2 Global Recombinant DNA Drug Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Recombinant DNA Drug Key Company Head office and Area Served
  4. 3.4 Global Recombinant DNA Drug Company, Product Type & Application
  5. 3.5 Global Recombinant DNA Drug Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Recombinant DNA Drug Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Recombinant DNA Drug Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Recombinant DNA Drug Tier 1, Tier 2, and Tier 3
4 Recombinant DNA Drug Market by Type
  1. 4.1 Global Recombinant DNA Drug Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Recombinant DNA Drug Market Size by Type (2021-2032)
  3. 4.3 Global Recombinant DNA Drug Market Size Share by Type (2021-2032)
5 Recombinant DNA Drug Market by Application
  1. 5.1 Global Recombinant DNA Drug Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Recombinant DNA Drug Market Size by Application (2021-2032)
  3. 5.3 Global Recombinant DNA Drug Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 GenSci
  2. 6.1.1 GenSci Company Information
  3. 6.1.2 GenSci Business Overview
  4. 6.1.3 GenSci Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 GenSci Recombinant DNA Drug Product Portfolio
  6. 6.1.5 GenSci Recent Developments
  7. 6.2 Takeda
  8. 6.2.1 Takeda Company Information
  9. 6.2.2 Takeda Business Overview
  10. 6.2.3 Takeda Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Takeda Recombinant DNA Drug Product Portfolio
  12. 6.2.5 Takeda Recent Developments
  13. 6.3 CSPC
  14. 6.3.1 CSPC Company Information
  15. 6.3.2 CSPC Business Overview
  16. 6.3.3 CSPC Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 CSPC Recombinant DNA Drug Product Portfolio
  18. 6.3.5 CSPC Recent Developments
  19. 6.4 3SBIO
  20. 6.4.1 3SBIO Company Information
  21. 6.4.2 3SBIO Business Overview
  22. 6.4.3 3SBIO Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 3SBIO Recombinant DNA Drug Product Portfolio
  24. 6.4.5 3SBIO Recent Developments
  25. 6.5 Sandoz
  26. 6.5.1 Sandoz Company Information
  27. 6.5.2 Sandoz Business Overview
  28. 6.5.3 Sandoz Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Sandoz Recombinant DNA Drug Product Portfolio
  30. 6.5.5 Sandoz Recent Developments
  31. 6.6 Sanofi
  32. 6.6.1 Sanofi Company Information
  33. 6.6.2 Sanofi Business Overview
  34. 6.6.3 Sanofi Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Sanofi Recombinant DNA Drug Product Portfolio
  36. 6.6.5 Sanofi Recent Developments
  37. 6.7 Johnson & Johnson
  38. 6.7.1 Johnson & Johnson Company Information
  39. 6.7.2 Johnson & Johnson Business Overview
  40. 6.7.3 Johnson & Johnson Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Johnson & Johnson Recombinant DNA Drug Product Portfolio
  42. 6.7.5 Johnson & Johnson Recent Developments
  43. 6.8 Novo Nordisk
  44. 6.8.1 Novo Nordisk Company Information
  45. 6.8.2 Novo Nordisk Business Overview
  46. 6.8.3 Novo Nordisk Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Novo Nordisk Recombinant DNA Drug Product Portfolio
  48. 6.8.5 Novo Nordisk Recent Developments
  49. 6.9 Merck
  50. 6.9.1 Merck Company Information
  51. 6.9.2 Merck Business Overview
  52. 6.9.3 Merck Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Merck Recombinant DNA Drug Product Portfolio
  54. 6.9.5 Merck Recent Developments
  55. 6.10 Roche
  56. 6.10.1 Roche Company Information
  57. 6.10.2 Roche Business Overview
  58. 6.10.3 Roche Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Roche Recombinant DNA Drug Product Portfolio
  60. 6.10.5 Roche Recent Developments
  61. 6.11 Eli Lilly
  62. 6.11.1 Eli Lilly Company Information
  63. 6.11.2 Eli Lilly Business Overview
  64. 6.11.3 Eli Lilly Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Eli Lilly Recombinant DNA Drug Product Portfolio
  66. 6.11.5 Eli Lilly Recent Developments
  67. 6.12 Pfizer
  68. 6.12.1 Pfizer Company Information
  69. 6.12.2 Pfizer Business Overview
  70. 6.12.3 Pfizer Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Pfizer Recombinant DNA Drug Product Portfolio
  72. 6.12.5 Pfizer Recent Developments
  73. 6.13 GlaxoSmithKline
  74. 6.13.1 GlaxoSmithKline Company Information
  75. 6.13.2 GlaxoSmithKline Business Overview
  76. 6.13.3 GlaxoSmithKline Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 GlaxoSmithKline Recombinant DNA Drug Product Portfolio
  78. 6.13.5 GlaxoSmithKline Recent Developments
  79. 6.14 Biogen
  80. 6.14.1 Biogen Company Information
  81. 6.14.2 Biogen Business Overview
  82. 6.14.3 Biogen Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Biogen Recombinant DNA Drug Product Portfolio
  84. 6.14.5 Biogen Recent Developments
  85. 6.15 Bayer
  86. 6.15.1 Bayer Company Information
  87. 6.15.2 Bayer Business Overview
  88. 6.15.3 Bayer Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Bayer Recombinant DNA Drug Product Portfolio
  90. 6.15.5 Bayer Recent Developments
  91. 6.16 Bristol-Myers Squibb
  92. 6.16.1 Bristol-Myers Squibb Company Information
  93. 6.16.2 Bristol-Myers Squibb Business Overview
  94. 6.16.3 Bristol-Myers Squibb Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 Bristol-Myers Squibb Recombinant DNA Drug Product Portfolio
  96. 6.16.5 Bristol-Myers Squibb Recent Developments
  97. 6.17 Amgen
  98. 6.17.1 Amgen Company Information
  99. 6.17.2 Amgen Business Overview
  100. 6.17.3 Amgen Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 Amgen Recombinant DNA Drug Product Portfolio
  102. 6.17.5 Amgen Recent Developments
  103. 6.18 AbbVie
  104. 6.18.1 AbbVie Company Information
  105. 6.18.2 AbbVie Business Overview
  106. 6.18.3 AbbVie Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 AbbVie Recombinant DNA Drug Product Portfolio
  108. 6.18.5 AbbVie Recent Developments
  109. 6.19 Swedish Orphan Biovitrum
  110. 6.19.1 Swedish Orphan Biovitrum Company Information
  111. 6.19.2 Swedish Orphan Biovitrum Business Overview
  112. 6.19.3 Swedish Orphan Biovitrum Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  113. 6.19.4 Swedish Orphan Biovitrum Recombinant DNA Drug Product Portfolio
  114. 6.19.5 Swedish Orphan Biovitrum Recent Developments
  115. 6.20 Organon Pharma
  116. 6.20.1 Organon Pharma Company Information
  117. 6.20.2 Organon Pharma Business Overview
  118. 6.20.3 Organon Pharma Recombinant DNA Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
  119. 6.20.4 Organon Pharma Recombinant DNA Drug Product Portfolio
  120. 6.20.5 Organon Pharma Recent Developments
7 North America
  1. 7.1 North America Recombinant DNA Drug Market Size (2021-2032)
  2. 7.2 North America Recombinant DNA Drug Market Size by Type
  3. 7.2.1 North America Recombinant DNA Drug Market Size by Type (2021-2026)
  4. 7.2.2 North America Recombinant DNA Drug Market Size by Type (2027-2032)
  5. 7.2.3 North America Recombinant DNA Drug Market Share by Type (2021-2032)
  6. 7.3 North America Recombinant DNA Drug Market Size by Application
  7. 7.3.1 North America Recombinant DNA Drug Market Size by Application (2021-2026)
  8. 7.3.2 North America Recombinant DNA Drug Market Size by Application (2027-2032)
  9. 7.3.3 North America Recombinant DNA Drug Market Share by Application (2021-2032)
  10. 7.4 North America Recombinant DNA Drug Market Size by Country
  11. 7.4.1 North America Recombinant DNA Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Recombinant DNA Drug Market Size by Country (2021-2026)
  13. 7.4.3 North America Recombinant DNA Drug Market Size by Country (2027-2032)
  14. 7.4.4 North America Recombinant DNA Drug Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Recombinant DNA Drug Market Size (2021-2032)
  2. 8.2 Europe Recombinant DNA Drug Market Size by Type
  3. 8.2.1 Europe Recombinant DNA Drug Market Size by Type (2021-2026)
  4. 8.2.2 Europe Recombinant DNA Drug Market Size by Type (2027-2032)
  5. 8.2.3 Europe Recombinant DNA Drug Market Share by Type (2021-2032)
  6. 8.3 Europe Recombinant DNA Drug Market Size by Application
  7. 8.3.1 Europe Recombinant DNA Drug Market Size by Application (2021-2026)
  8. 8.3.2 Europe Recombinant DNA Drug Market Size by Application (2027-2032)
  9. 8.3.3 Europe Recombinant DNA Drug Market Share by Application (2021-2032)
  10. 8.4 Europe Recombinant DNA Drug Market Size by Country
  11. 8.4.1 Europe Recombinant DNA Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Recombinant DNA Drug Market Size by Country (2021-2026)
  13. 8.4.3 Europe Recombinant DNA Drug Market Size by Country (2027-2032)
  14. 8.4.4 Europe Recombinant DNA Drug Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Recombinant DNA Drug Market Size (2021-2032)
  2. 9.2 China Recombinant DNA Drug Market Size by Type
  3. 9.2.1 China Recombinant DNA Drug Market Size by Type (2021-2026)
  4. 9.2.2 China Recombinant DNA Drug Market Size by Type (2027-2032)
  5. 9.2.3 China Recombinant DNA Drug Market Share by Type (2021-2032)
  6. 9.3 China Recombinant DNA Drug Market Size by Application
  7. 9.3.1 China Recombinant DNA Drug Market Size by Application (2021-2026)
  8. 9.3.2 China Recombinant DNA Drug Market Size by Application (2027-2032)
  9. 9.3.3 China Recombinant DNA Drug Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Recombinant DNA Drug Market Size (2021-2032)
  2. 10.2 Asia Recombinant DNA Drug Market Size by Type
  3. 10.2.1 Asia Recombinant DNA Drug Market Size by Type (2021-2026)
  4. 10.2.2 Asia Recombinant DNA Drug Market Size by Type (2027-2032)
  5. 10.2.3 Asia Recombinant DNA Drug Market Share by Type (2021-2032)
  6. 10.3 Asia Recombinant DNA Drug Market Size by Application
  7. 10.3.1 Asia Recombinant DNA Drug Market Size by Application (2021-2026)
  8. 10.3.2 Asia Recombinant DNA Drug Market Size by Application (2027-2032)
  9. 10.3.3 Asia Recombinant DNA Drug Market Share by Application (2021-2032)
  10. 10.4 Asia Recombinant DNA Drug Market Size by Country
  11. 10.4.1 Asia Recombinant DNA Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Recombinant DNA Drug Market Size by Country (2021-2026)
  13. 10.4.3 Asia Recombinant DNA Drug Market Size by Country (2027-2032)
  14. 10.4.4 Asia Recombinant DNA Drug Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Recombinant DNA Drug Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Recombinant DNA Drug Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Recombinant DNA Drug Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Recombinant DNA Drug Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Recombinant DNA Drug Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Recombinant DNA Drug Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Recombinant DNA Drug Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Recombinant DNA Drug Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Recombinant DNA Drug Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Recombinant DNA Drug Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Recombinant DNA Drug Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Recombinant DNA Drug Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Recombinant DNA Drug Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Recombinant DNA Drug Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst